Home Casteddu Flying Publisher
 
 



 
 
 
 
 
 
 
 


 
HIV-Therapie 2008

Empfehlungen der Internationalen AIDS-Gesellschaft

Die International AIDS Society hat die 2008er Empfehlungen für die HIV-Therapie veröffentlicht.

HTML - PDF



Welt-AIDS-Kongress

Vom 3. bis 8. August fand in Mexico der 17. Internationale AIDS-Kongress statt. Die wichtigsten Beiträge zur antiretroviralen Therapie (ART) der HIV-Infektion, zusammengestellt von Johannes Morgenstern.



8. August  

Abstracts

  1. Response to antiretroviral therapy in HIV-positive migrants of Sub-Saharan African origin within the Swiss HIV Cohort Study (SHCS) Abstract THAB0502

  2. Virologic response to HAART among incarcerated HIV+ individuals Abstract THAB0503

  3. The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Abstract THAB0504

  4. Decreasing initiation of HAART therapy and reduced immunologic competence among injection drug users, 1996-2006, Baltimore, MD USA Abstract THAB0505

  5. Barriers to HIV care and antiretroviral treatment (ART) among HIV-infected crack users in the United States Abstract THAB0506

  6. Can unsafe sex be safe? Review of sexual transmissibility of HIV-1 according to viral load, HAART, and sexually transmitted infections Abstract THAC0505

  7. The protective effect of male circumcision is sustained for at least 42 months: results from the Kisumu, Kenya Trial Abstract THAC0501


 
7. August

Video-Aufzeichnungen (ART und andere Themen)

  1. Late Breaker 1
    • A randomized, double-blind, placebo-controlled, multicenter trial of pregabalin vs placebo in the treatment of neuropathic pain associated with HIV neuropathy
    • Cost-effectiveness of programmatic models for provision of antiretroviral therapy in resource-limited settings
    • ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA ³100,000 c/mL
    • Abacavir/lamivudine (ABC/3TC) shows robust virologic responses in ART-naïve patients for baseline (BL) viral loads (VL) of ³100,000c/mL and <100,000c/mL by endpoint used in ACTG5202
    • Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study

  2. Male Circumcision: To Cut or Not to Cut
    • The evidence: Does circumcision really work?
    • The meaning of circumcision for young men
    • Cultural and religious sensitivities
    • The implications for women and for MSM
    • Implications of circumcision for MSM
    • Traditional practices and effective prevention

  3. Late Breaker 2
    • High prevalence of acute HIV infection in Sub-Saharan Africa: a cross sectional, multi-centre screening study
    • IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naïve HIV-1-infected subjects
    • Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of näive HIV patients
    • PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection
    • A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects
    • High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial

  4. The Future of Microbicides: From Vaginal ART to PREP
    • Future promising microbicidal products: What to learn from the invitro work
    • ART containing vaginal microbicides in the clinical pipeline: A status of the studies
    • Pre-exposure prophylaxis: Overview of current and planned trials
    • The use of oral and topical PREP at population level: What are the issues
 

Abstracts

  1. High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial. Abstract THAB0406

  2. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA >=100,000 c/mL. Abstract THAB0303

  3. PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection. Abstract THAB0404

  4. Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of näive HIV patients. Abstract THAB0403

  5. IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naïve HIV-1-infected subjects. Abstract THAB0402

  6. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. Abstract THAB0305

  7. A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects. Abstract THAB0405

  8. HCV relapses upon completion of peg-interferon plus Ribavirin in HIV-infected patients: rate, timing and predictors. Abstract THAB0202


 
6. August

Video-Aufzeichnungen (andere Themen)

  1. The USA HIV Epidemic in 2008
    • Introduction to the topic
    • HIV/AIDS in the States: Current trends and future challenges
    • The HIV/AIDS epidemic in MSM in the United States
    • Trends in HIV-related risk behaviors among US adolescents: is progress stalling?
    • Efficacy of an intervention in reducing HIV risk behaviors, non-viral STIs and HPV among African-American women: results of a randomized controlled trial
    • Housing status and HIV risk behaviors among homeless and housed persons with HIV in the United States

  2. Human Security and HIV
    • Gender, security, and HIV
    • Conflict and post-conflict in Africa
    • Human security and HIV
    • Humanitarian crises and HIV

  3. Looking to the Future--The Epidemic in 2031 and New Directions in AIDS Research
    • The future of AIDS research
    • '2031 initiative' . Looking to the year 2031 and anticipating where we are likely to be in terms of the epidemic and the response
    • The future of AIDS advocacy
    • The future of AIDS advocacy
    • The future of AIDS advocacy


 
5. August

Video-Aufzeichnungen (ART und andere Themen)

  1. Newer Antiretroviral Agents
    • Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data
    • TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naïve patients: 96-week results of study C204
    • A prospective, randomized, open label trial of efavirenz versus lopinavir/ritonavir based HAART among antiretroviral therapy naïve, HIV infected individuals presenting for care with CD4 cell counts <200/mm3 in Mexico
    • Resistance profile of patients failing first line ART in Malawi when using clinical and immunologic monitoring
    • Safety profile of apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients

  2. The Lancet Series on HIV Prevention
    • The history and challenge of HIV prevention
    • Biomedical interventions to prevent HIV: Evidence, challenges and the way forward
    • Behavioral strategies to reduce HIV transmission: How to make them work better
    • Understanding and addressing structural factors in HIV prevention
    • Making HIV prevention programmes work
    • Coming to terms with complexity: A call to action for HIV prevention

  3. Travel Restrictions on People Living with HIV: Going Against the Grain of Human Rights and Public Health
    • Discussion of US efforts to end discriminatory HIV-related travel, entry restrictions, laws and policies
    • The impact of short and long term travel restrictions on people living with HIV and their families
    • Experiences of a country of origin for international labor migration
    • Experience of reversing laws on HIV-related short term travel restrictions
    • Experiences of the Global Fund and the history of advocacy to fight travel restrictions against PLWHA, including the International AIDS Conference
    • Human rights, ethical and legal considerations
    • On the lack of a public health rationale for restricting entry of PLWHA
 

Abstracts

  1. Transmission of resistant HIV strains in patients with documented date of HIV infection in the German HIV seroconverter cohort (1997-2007). A decade of observation. Abstract TUAA0204

  2. Primary HIV drug resistance surveillance in Canada. Abstract TUAA0203

  3. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data. Abstract TUAB0102

  4. TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naïve patients: 96-week results of study C204. Abstract TUAB0103

  5. Safety profile of apricitabine, a novel NRTI, during 24-week dosing in experienced HIV-1 infected patients. Abstract TUAB0106

  6. Trends in mortality in the pre- and post-HAART eras among HIV-infected children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004). Abstract TUPDB102

  7. Low emergence of drug resistance after HAART interruption at delivery in a cohort of HIV+ pregnant women in Rio de Janeiro, Brazil. Abstract TUAA0304

  8. Connection domain mutations are common in treatment-experienced patients and are associated with virologic outcome. Abstract TUAA0301


 
4. August

Video-Aufzeichnungen (andere Themen)

  1. Is Religion a Barrier to HIV Prevention? (90 Minuten)
    • Sex, gender, and religion in HIV
    • Religion, sex, and HIV prevention
    • Islam and HIV prevention
    • Religion and HIV in Papua New Guinea
    • Challenges and lessons learned in involving religious leaders in HIV prevention Modibo Maiga, Mali

  2. New Insights into HIV Transmission and Pathogenesis (95 Minuten)
    • Determinants of HIV transmission
    • Novel animal models for HIV transmission and pathogenesis
    • Host restriction in T cells and macrophages
    • Immune basis of HIV pathogenesis

  3. Vaccines and Microbicides: Where Do We go from Here? (113 Minuten)
    • Overview of current challenges
    • An HIV vaccine: Where do we go from here?
    • STEP vaccine trial lessons learned
    • New priorities for IAVI
    • ARV-based Microbicides: Cause for Optimism
    • Recent microbicide trials and lessons learned
    • Microbicide community mobilization and trial participation
    • Vaccine advocacy and community leadership in the south
 

Abstracts

  1. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study. Abstract MOPDB103

  2. Early improvement of limb fat content in patients switching from AZT/3TC to FTC/TDF (TVD): a 24 week interim analysis of the RECOMB trial. Abstract MOPDB102

  3. First-line HAART guided by genotypic resistance testing - long-term follow-up data from the RESINA-study. Abstract MOPDA201

  4. Mitochondrial RNA and DNA alterations in subcutaneous fat tissue of HIV+ subjects with lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Abstract MOPDB106

  5. Impact of highly active antiretroviral therapy on the incidence of HIV-encephalopathy among perinatally-infected children and adolescents. Abstract MOAB0103

  6. Response to HAART in naïve patients with a diagnosis of tuberculosis. Abstract MOPDB204

  7. Extensively drug-resistant tuberculosis - case analysis 2003/2007 Abstract MOPDB207


 
3. August

Video-Aufzeichnung

HIV Transmission under ART (114 Minuten)

Schon am Eröffnungstag wurde über das EKAF-Paper "HIV-infizierte Menschen ohne andere STD sind unter wirksamer antiretroviraler Therapie sexuell nicht infektiös" diskutiert (Schweizerische Ärztezeitung, siehe PDF).

Die Beiträge zu diesem Thema:

  1. The International Aids Society view
    Julio Montaner, Canada

  2. Summary of the Geneva's Closed Hearing on HIV Transmission under ART
    Pietro Vernazza, Switzerland

  3. HIV Transmission risk under ART
    Myron Cohen, United States

  4. Prevention implications
    Nancy Padian, United States

  5. What are the consequences of the Swiss statement for the rest of the world?
    Catherine Hankins, Switzerland

  6. The view of the civil society
    Nikos Dedes, Greece

  7. Satellite Conclusions
    Bernard Hirschel, Switzerland
Bei Fragen wenden Sie sich bitte an
luciano.ruggia {at} bag.admin.ch.


 

 
 

Design:

 
 
 

    HIV + ART ist ein Flying Publisher Website.